Epoxyeicosatrienoic acids are involved in the C(70) fullerene derivative-induced control of allergic asthma.
about
Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitorA work group report on ultrafine particles (American Academy of Allergy, Asthma & Immunology): Why ambient ultrafine and engineered nanoparticles should receive special attention for possible adverse health outcomes in human subjectsPotential Suppressive Effects of Two C60 Fullerene Derivatives on Acquired ImmunityFunctionalization of gadolinium metallofullerenes for detecting atherosclerotic plaque lesions by cardiovascular magnetic resonance.Resolution of sterile inflammation: role for vitamin CApplication of fullerenes in nanomedicine: an update.Inhibition of inflammatory arthritis using fullerene nanomaterials.Increased B Cell ADAM10 in Allergic Patients and Th2 Prone MiceSoluble epoxide hydrolase inhibitor 1-trifluoromethoxyphenyl-3- (1-propionylpiperidin-4-yl) urea attenuates bleomycin-induced pulmonary fibrosis in mice.Arachidonic acid-derived signaling lipids and functions in impaired healing.Characterization of eicosanoid synthesis in a genetic ablation model of ceramide kinaseLiposome formulation of fullerene-based molecular diagnostic and therapeutic agents.Recent advances in the use of nanoparticles for allergen-specific immunotherapy.A steroid-mimicking nanomaterial that mediates inhibition of human lung mast cell responsesMechanistic insight into the impact of nanomaterials on asthma and allergic airway disease.Atomic force microscopy study of the effects of water-soluble fullerenes on the elasticity of living plant cells.Modulation of Immune Responses by Particulate Materials.
P2860
Q28270421-B82AB576-E3F6-464C-BC19-73114DFE004FQ28385963-09314CBB-582E-4E7E-A6BF-D9F2FE1E507AQ28390965-6620CC88-BEDA-41D7-839D-51F29BB2F67EQ30533932-5C862432-D9A4-4BAF-BE63-BBDE55169C77Q34245269-5AD10992-19B9-4825-8B73-6D8685010285Q34803596-9E11C4C4-C00B-41AB-9057-B650A22438F7Q35448218-B5004296-B00C-404D-BAB7-2C134DD77E6BQ35620247-1BCCFA03-35B4-4062-A6F0-90224A9B9985Q36535579-A3FCC9C6-8649-4E6D-B1C9-30E3F314D7A8Q36815776-82A8B727-23DD-4DF6-8AC4-2817BA4F9744Q36920571-B23F0125-0D26-42B2-B006-AF8EA6FF5A74Q37415965-35A54A91-748A-4F2A-8920-B52BBD0327FCQ38802840-D35353B5-CF1E-4B3E-8411-781514631FEEQ42543826-40E55505-3BB7-429A-B714-6BD2DCBEE326Q45817911-7F97ED5A-81DF-4E4E-978E-E321287DDD8EQ46977830-A3A320D4-8B43-4C12-9D4E-03D1A553D991Q51336724-A017D4A8-D1AF-4D3C-8A53-5B2A35C04EED
P2860
Epoxyeicosatrienoic acids are involved in the C(70) fullerene derivative-induced control of allergic asthma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 June 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Epoxyeicosatrienoic acids are involved in the C
@nl
Epoxyeicosatrienoic acids are ...... ed control of allergic asthma.
@en
type
label
Epoxyeicosatrienoic acids are involved in the C
@nl
Epoxyeicosatrienoic acids are ...... ed control of allergic asthma.
@en
prefLabel
Epoxyeicosatrienoic acids are involved in the C
@nl
Epoxyeicosatrienoic acids are ...... ed control of allergic asthma.
@en
P2093
P2860
P1476
Epoxyeicosatrienoic acids are ...... ed control of allergic asthma.
@en
P2093
Anthony Dellinger
Charles Chalfant
Christopher L Kepley
Daniel H Conrad
Dayanjan S Wijesinghe
Sarah K Norton
Suzanne Barbour
Zhiguo Zhou
P2860
P304
761-769.e2
P356
10.1016/J.JACI.2012.04.023
P407
P577
2012-06-02T00:00:00Z